Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice

被引：0
|
作者：
Krekeler, G. [1 ]
Neuhof, A. [1 ]
Dreyling, M. [2 ]
Hess, G. [3 ]
Kalanovic, D. [1 ]
机构：
[1] Pfizer Pharma GmbH, Berlin, Germany
[2] Univ Munich, Munich, Germany
[3] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany
来源：
Oncology Research and Treatment | 2015年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P226
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [41] Evaluation of safety, tolerability and activity of Temsirolimus in patients (pts) with advanced or metastatic renal cell carcinoma (a/mRCC) in routine clinical practice
    Woike, M.
    Strunz, A. M.
    Krekeler, G.
    Bergmann, L.
    Steiner, T.
    Goebel, P. J.
    Goehler, T.
    Harich, H. -D.
    Herrmann, E.
    Rebmann, U.
    Kalanovic, D.
    Oncology Research and Treatment, 2015, 38 : 83 - 83
  • [42] IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
    Juan-Manuel Sancho
    Ana Marín-Niebla
    Silvia Fernández
    Francisco-Javier Capote
    Carolina Cañigral
    Carlos Grande
    Eva Donato
    Izaskun Zeberio
    Jose-Manuel Puerta
    Alfredo Rivas
    Elena Pérez-Ceballos
    Ana Vale
    Alejandro Martín García-Sancho
    Antonio Salar
    Eva González-Barca
    Anabel Teruel
    Carmen Pastoriza
    Diego Conde-Royo
    Joaquín Sánchez-García
    Cristina Barrenetxea
    Reyes Arranz
    José-Ángel Hernández-Rivas
    María-José Ramírez
    Aroa Jiménez
    Eva Rubio-Azpeitia
    International Journal of Hematology, 2022, 116 : 381 - 392
  • [43] IBRORS-LCM: A SPANISH RETROSPECTIVE, OBSERVATIONAL, RETROSPECTIVE STUDY OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) TREATED WITH IBRUTINIB IN ROUTINE CLINICAL PRACTICE
    Sancho, Juan-Manuel
    Marin, Ana
    Fernandez, Silvia
    Capote, Francisco-Javier
    Canigral, Carolina
    Grande, Carlos
    Donato, Eva
    Zeberio, Izaskun
    Puerta, Jose-Manuel
    Rivas, Alfredo
    Perez-Ceballos, Elena
    Vale, Ana
    Jimenez, Aroa
    Loriente, Cristina
    HAEMATOLOGICA, 2020, 105 : 93 - 93
  • [44] IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
    Sancho, Juan-Manuel
    Marin-Niebla, Ana
    Fernandez, Silvia
    Capote, Francisco-Javier
    Canigral, Carolina
    Grande, Carlos
    Donato, Eva
    Zeberio, Izaskun
    Puerta, Jose-Manuel
    Rivas, Alfredo
    Perez-Ceballos, Elena
    Vale, Ana
    Martin Garcia-Sancho, Alejandro
    Salar, Antonio
    Gonzalez-Barca, Eva
    Teruel, Anabel
    Pastoriza, Carmen
    Conde-Royo, Diego
    Sanchez-Garcia, Joaquin
    Barrenetxea, Cristina
    Arranz, Reyes
    Hernandez-Rivas, Jose-Angel
    Ramirez, Maria-Jose
    Jimenez, Aroa
    Rubio-Azpeitia, Eva
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (03) : 381 - 392
  • [45] EVALUATION OF SAFETY, TOLERABILITY AND ACTIVITY OF TEMSIROLIMUS IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA (A/MRCC) IN ROUTINE CLINICAL PRACTICE
    Woike, M.
    Bergmann, L.
    Steiner, T.
    Goebell, P. J.
    Goehler, T.
    Harich, H.
    Herrmann, E.
    Rebmann, U.
    Kalanovic, D.
    ANNALS OF ONCOLOGY, 2014, 25
  • [46] Concurrent involved field radiation therapy and Temsirolimus in refractory mantle cell lymphoma (MCL)
    Kirova, Youlia M.
    Chargari, Cyrus
    Amessis, Malika
    Vernant, Jean-Paul
    Dhedin, Nathalie
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (11) : 892 - 892
  • [47] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Myron S. Czuczman
    A. Goy
    D. Lamonica
    D. A. Graf
    M. C. Munteanu
    R. H. van der Jagt
    Annals of Hematology, 2015, 94 : 2025 - 2032
  • [48] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Czuczman, Myron S.
    Goy, A.
    Lamonica, D.
    Graf, D. A.
    Munteanu, M. C.
    van der Jagt, R. H.
    ANNALS OF HEMATOLOGY, 2015, 94 (12) : 2025 - 2032
  • [49] Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
    Freeman, Ciara L.
    Pararajalingam, Prasath
    Jin, Ling
    Balasubramanian, Sriram
    Jiang, Aixiang
    Xu, Wendan
    Grau, Michael
    Zapukhlyak, Myroslav
    Boyle, Merrill
    Hodkinson, Brendan
    Schaffer, Michael
    Enny, Christopher
    Deshpande, Sanjay
    Sun, Steven
    Vermeulen, Jessica
    Morin, Ryan D.
    Scott, David W.
    Lenz, Georg
    LEUKEMIA, 2022, 36 (10) : 2479 - 2487
  • [50] Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
    Ciara L. Freeman
    Prasath Pararajalingam
    Ling Jin
    Sriram Balasubramanian
    Aixiang Jiang
    Wendan Xu
    Michael Grau
    Myroslav Zapukhlyak
    Merrill Boyle
    Brendan Hodkinson
    Michael Schaffer
    Christopher Enny
    Sanjay Deshpande
    Steven Sun
    Jessica Vermeulen
    Ryan D. Morin
    David W. Scott
    Georg Lenz
    Leukemia, 2022, 36 : 2479 - 2487
12345